Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

Inclusion Criteria:

Have a diagnosis of plaque-type psoriasis with or without psoriatic arthritis (PsA) for at least 6 months before Day 1
Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at Screening
Have an Investigator's Global Assessment (IGA) >= 3 at Screening
Have an involved body surface area (BSA) >= 10 percent (%) at Screening
Be a candidate for phototherapy or systemic treatment for psoriasis

Exclusion Criteria:

Has a history of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac (including unstable cardiovascular disease, defined as a recent clinical deterioration (example, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months), vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, bleeding disorder, rheumatologic, psychiatric, or metabolic disturbances
Have a pulse oximetry value less than (<) 94 % at Screening
Genetically determined poor metabolizers of CYP2C9, CYP2C19, and CYP2D6 substrates
Is currently undergoing or has previously undergone allergy immunotherapy for a history of anaphylactic reactions
Has a transplanted organ (with exception of a corneal transplant greater than (>) 3 months before Day 1)